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Abstract
The magnitude of the HIV epidemic in women requires urgent efforts to find effective preventive methods. Even though sex
hormones have been described to influence HIV infection in epidemiological studies and regulate different immune
responses that may affect HIV infection, the direct role that female sex hormones play in altering the susceptibility of target
cells to HIV-infection is largely unknown. Here we evaluated the direct effect of 17-b-estradiol (E2) and ethinyl estradiol (EE)
in HIV-infection of CD4+ T-cells and macrophages. Purified CD4+ T-cells and monocyte-derived macrophages were
generated in vitro from peripheral blood and infected with R5 and X4 viruses. Treatment of CD4+ T-cells and macrophages
with E2 prior to viral challenge reduced their susceptibility to HIV infection in a dose-dependent manner. Addition of E2 2 h
after viral challenge however did not result in reduced infection. In contrast, EE reduced infection in macrophages to a lesser
extent than E2 and had no effect on CD4
+ T-cell infection. Reduction of HIV-infection induced by E2 in CD4
+ T-cells was not
due to CCR5 down-regulation, but was an entry-mediated mechanism since infection with VSV-G pseudotyped HIV was not
modified by E2. In macrophages, despite the lack of an effect of E2 on CCR5 expression, E2–treatment reduced viral entry 2 h
after challenge and increased MIP-1b secretion. These results demonstrate the direct effect of E2 on susceptibility of HIV-
target cells to infection and indicate that inhibition of target cell infection involves cell-entry related mechanisms.
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Introduction
Heterosexual transmission of HIV-1 remains a worldwide
health challenge that is responsible for most HIV-1 transmissions
to women (70–90%) [1]. Globally, young women are most
vulnerable to HIV-1 infection, with rates of infection twice as high
as young men, and as much as eight times higher in Sub-Saharan
Africa, where women account for 59% of people living with HIV-
1 [2,3]. Furthermore, globally HIV-1 is the leading cause of death
for women of reproductive age [2].
Gender discrepancies regarding HIV-1 infection and disease
progression have been repeatedly reported and are due to
hormonal differences among other factors [4,5]. While plasma
viral loads are lower in HIV-infected women compared to men,
the rate of disease progression is greater in women [6,7].
Additionally, sex hormone fluctuations in women have been
associated with both protective and adverse effects. For example,
relative to the follicular and luteal phases of the menstrual cycle,
decreases in plasma viral load at ovulation, when estradiol levels
are high, have been previously described [8], although others did
not find any effect of the menstrual cycle on HIV-RNA levels in
blood [9]. In contrast, analysis of genital secretions throughout the
menstrual cycle demonstrated increased HIV-1 shedding during
the luteal phase, when progesterone levels are higher, in some
reports [9,10] while others did not find any pattern of genital tract
shedding during the menstrual cycle [11]. More recently,
significant positive associations were found between the number
of days from the luteinizing hormone surge and the number of
endocervical HIV-infected cells [12]. Furthermore, serum estra-
diol levels in women are inversely correlated with AIDS-induced
dementia [13,14]. Additionally, studies conducted in macaques
showed that intravaginal treatment with estriol for weeks prior to
SIV vaginal challenge was able to protect. Protection was
attributed to a cornification and thickening of the vaginal epithelia
[15]. Despite the fact that associations between sex hormones and
HIV-infection have been established, the underlying cellular and
molecular mechanisms remain poorly understood.
17-b-estradiol (E2) is the main estrogen found in blood of
women and exerts its actions through binding to the estrogen
receptors (ER) present in the reproductive tract tissues and in
immune cells in peripheral blood, including CD4+ T-cells and
macrophages, the two main HIV-target cells [16,17]. Binding of
E2 to its receptors results in modulation of the expression of
multiple genes. Studies by others and us illustrate the broad
spectrum of actions of E2 on immune cells and the innate and
adaptive immune response, including molecules and pathways
involved in anti-viral innate immune responses [18,19,20]. With
the exception of studies with isolated cells from the central nervous
system or cell lines [21,22,23], very little is known about the direct
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e62069
effects of sex hormones on HIV-infection of immune cells.
Interestingly, Asin et al examined the effects of sex hormones on
HIV-infection and reported that different doses and combinations
of estradiol and progesterone were able to regulate HIV-1
replication in peripheral blood mononuclear cells [24]. Therefore,
a gap remains in our understanding of the direct effects of E2 in
modulating susceptibility of CD4+ T-cells and macrophages to
HIV-infection.
In this study we evaluated the effects of E2 on HIV infection of
CD4+ T-cells and macrophages. We found a dose-dependent
reduction of HIV-infection by E2 in both cell types, through a
mechanism that affected the early steps of the viral cycle but was
not due to CCR5 down-regulation.
Materials and Methods
Study Subjects
All investigations involving human subjects were conducted
according to the principles expressed in the Declaration of
Helsinki and carried out with the approval from the Committee
for the Protection of Human Subjects (CPHS), Dartmouth
Hitchcock Medical Center, and with written informed consent
obtained from volunteer healthy donors recruited at Dartmouth
Hitchcock Medical Center. Blood donors were anonymous, so no
information regarding age or hormonal status was available and
only gender information was disclosed.
Generation of CD4+ T-cells and macrophages
Peripheral blood mononuclear cells (PBMC) were isolated by
standard Ficoll density gradient centrifugation. To generate
monocyte-derived macrophages, CD14+ cells were positively
selected with magnetic beads (Miltenyi Biotech, Auburn, CA)
and incubated in ultra-low attachment 6-well plates (Corning,
Corning, NY) with Xvivo 15 media (Lonza, Walkersville, MD)
supplemented with 10% human AB serum (Valley Biomedical,
Winchester, VA) for 4 days [25]. CD4+ T-cells were purified from
PBMC using magnetic negative selection (Miltenyi Biotech) and
activated in vitro using the same media described above supple-
mented with Phytohemagglutinin (PHA) (2.5 mg/ml; Sigma, St
Louis, MO) and IL-2 (50 U/ml) (AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: Human rIL-2
from Dr. Maurice Gately, Hoffmann- La Roche Inc) [26] for 1 to
3 days prior to HIV-infection. Purity higher than 98% was
obtained for both CD14+ cells and CD4+ T-cell populations after
magnetic isolation (not shown).
Hormone treatment
CD4+ T-cells and macrophages were treated either with 17b-
estradiol (E2; Sigma), 17a-ethinyl estradiol (EE) or Raloxifene (Rx;
Tocris Biosciences, Bristol, UK) as indicated in Results. CD4+ T-
cells were treated during activation prior to infection (1–3 days)
and/or following infection (6–7 days). Macrophages were treated
during differentiation period (4 days) and/or following infection
(6–7 days). For all hormone experiments E2, EE or Raloxifene
were dissolved in 100% ethanol for an initial concentration of
161023 M, evaporated to dryness and suspended in Xvivo 15
media (Invitrogen) containing 10% of charcoal dextran-stripped
human AB serum (Valley Biomedical) to a concentration of
161025 M. Dilutions were made to achieve final working
concentrations ranging from 561028 M to 5610210 M for E2
and EE. As a control, an equivalent amount of 100% ethanol
without dissolved hormone was initially evaporated [27]. All
control conditions contained evaporated ethanol as a control. For
experiments using estrogen receptor antagonist, Raloxifene was
added 30 min before E2 at a 100-fold excess concentration.
Viruses
Seed stock for HIV-1BaL (R5) was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, from Dr. Suzanne Gartner, Dr. Mikulas Popovic
and Dr. Robert Gallo [28]. Laboratory adapted viral strain HIV-
1IIIB was obtained from Dr. P. Gupta (University of Pittsburg, PA).
Viral stocks were prepared by infection of PBMC activated with
PHA (2.5 mg/ml and 50 U/ml IL-2) for 6-8 days as previously
described [29]. Stocks were harvested when p24 concentrations
reached 100 ng/ml. Titration of viral stocks was performed using
PHA-stimulated PBMC as described [29]. The replication-
competent GFP-encoding infectious molecular clone
(pNLENG1i-BaL.ecto) [30] was derived from pNLENG1-ires
[31] to express heterologous BaL env gene sequences in an isogenic
backbone following the strategy previously described [32,33]. This
reporter virus, collectively referred to as Env-IMC-GFP, expresses
GFP upon infection of HIV-1 susceptible target cells. The env-
defective, GFP encoding proviral plasmid pNLENG1-ES-ires was
previously described [31], was co-transfected with a VSV-G
expressing plasmid to yield infectious, non-replicating pseudovir-
ions.
HIV-Infection
Macrophages were infected as described previously with minor
modifications [25]. Briefly, macrophages were exposed to HIV-
BaL for 2 h at an MOI of 0.1 and then washed to remove residual
virus. CD4+ T-cells were infected with HIV-1 BaL or HIV-1 IIIB
also for 2 h at an MOI of 0.1 and residual virus was washed away.
Uninfected controls were incubated with medium without the
virus for the same amount of time. After incubation, washed
macrophage or CD4+ T-cell targets were plated in round bottom
ultra low attachment 96-well plates (Corning) with or without sex
hormones as indicated. Cell cultures were maintained for 6–7
days, with half of the well media collected and replaced with fresh
media on day 3. Levels of p24 were measured in conditioned
media by p24 ELISA (Advanced Bioscience Laboratories, Rock-
ville, MD), and intracellularly by flow cytometry (KC57-FITC;
Coulter, Danvers, MA). As a control to prove that detected p24
corresponds to de novo infection and not residual viral inocula,
CD4+ T-cells or macrophages were incubated with Zidovudine
(AZT; 10 mM) (AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH) during viral challenge (2 h) and
throughout the post-infection period. No cytotoxicity was observed
with this concentration of Zidovudine as measured by Trypan blue
exclusion (Trypan Blue Solution, HyClone Laboratories, Inc;
Logan, UT) at the end of the infection period.
Flow cytometry
Prior to HIV infection, cells were stained for surface markers
with the following antibody panels: The CD4+ T-cell panel
included CD4, CD3 (eBioscience, San Diego, CA), CCR5 (BD
Biosciences, San Jose, CA), CXCR4 (R&D, Minneapolis, MN),
CD25 (Biolegend, San Diego, CA) and HLA-DR (Miltenyi
Biotech). The panel for macrophages included CD14, CD4
(eBioscience), CD163 (Biolegend), CCR5 (BD Biosciences) and
DC-SIGN (R&D). After infection (6–7 days), intracellular levels of
p24 were analyzed. Briefly, cells were washed, fixed and
permeabilized following instructions with Cytofix/Cytoperm Plus
kit (BD Biosciences) for 20 min and stained for intracellular p24
with KC57-FITC antibody (Beckman Coulter) for 30 min.
Analysis was performed on BD FACSCanto flow cytometer (BD
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Biosciences) using FACSdiva software and data were analyzed
with the FlowJo software (Tree Star, Inc. Ashland, OR).
Expression of surface markers was measured by the percentage
of positive cells and the mean fluorescence intensity (MFI).
RNA isolation and quantitative RT-PCR analysis
Total RNA was extracted from CD4+ T-cells and macrophages
using the RNeasy kit (QIAGEN, Valencia, CA) with on-column
DNase digestion using the RNase-Free DNase set (Qiagen). RNA
was quantified and cDNA was generated with the iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA) as described. PCR was
conducted in duplicates using the 59 fluorogenic nuclease assay in
real-time quantitative PCR using TaqMan chemistry on the ABI
7300 Prism real-time PCR instrument (Applied Biosystems,
Carlsbad, CA). Primers and probe sets were obtained from
Applied Biosystems assays-on-demand (GAPDH, CCR5, ER1,
ER2). Amplification conditions and analysis were performed as
described before [27]. Briefly, PCR was conducted using the
following cycle parameters: 95uC, 12 min for 1 cycle (95uC, 20 s;
60uC, 1 min), for 40 cycles. Analysis was conducted using the
sequence detection software supplied with the ABI 7300. The
software calculates the threshold cycle (Ct) for each reaction and
this was used to quantify the amount of starting template in the
reaction. The Ct values for each set of duplicate reactions were
averaged for all subsequent calculations. A difference in Ct values
(DCt) was calculated for each gene by taking the mean Ct of each
gene of interest and subtracting the mean Ct for the housekeeping
gene GAPDH for each cDNA sample. Relative expression levels
were calculated using the formula 22DCt [34].
ELISA
Secretion of RANTES and MIP-1b was measured in culture
media from CD4+ T-cells and macrophages 3 days after HIV-
infection by using RANTES and MIP-1b DuoSet ELISA
development system (R&D, Minneapolis, MN) according to the
manufacturer’s instructions.
Statistical analysis
Data were analyzed with the GraphPad Prism 5.0 software.
Non-parametric test U-Mann Whitney or Wilcoxon paired test
was applied for the comparison of two groups. For the comparison
of three or more groups, the non-parametric Kruskal-Wallis test
followed by Dunns post-test was applied. In all cases, a two sided P
value ,0.05 was considered statistically significant.
Results
1. E2 reduces susceptibility of CD4
+ T-cells to HIV-
infection
To examine the direct effect of E2 on HIV-infection in an in vitro
infection assay, purified CD4+ T-cells (.98% purity) were
activated in vitro in the presence or absence of E2 for 3 days and
infected with R5 (HIV-1 BaL) or X4 (IIIB) viral strains in parallel.
Secreted and intracellular p24 was measured 7 days after infection
as an indication of viral replication.
As shown in Figure 1A, when CD4+T cells were treated with E2
prior to infection (pre) for 3 days, released p24 was significantly
reduced 7 days after infection with HIV-1BaL (56% reduction;
p = 0.024). However, when E2 was added for the entire length of
incubation (prepost) or 2 h after infection (post) no differences
were found compared to the control condition. This observation
was confirmed by a significant reduction in the expression of
intracellular p24 in CD4+ T-cells pre-treated with E2 before
infection (Figure 1B, top row). As seen in Figure 1C, addition of
AZT, prevents de novo infection of CD4+ T-cells indicating that
intracellular p24 detected is not residual inocula.
In contrast, pre-incubation of CD4+ T-cells with E2 did not
reduce infection levels with HIV-1IIIB, measured as released p24
(Figure 1A, right panel) or intracellular p24 (Figure 1B, bottom
row). As seen in Figure 1A (right side), addition of E2 2 h after
infection (post) slightly reduced p24 levels, but this tendency did
not reach statistical significance (p= 0.077). Since no differences
were found with HIV-1IIIB the following experiments focused on
HIV-1BaL.
The experiments described above were performed at a high
dose of E2 (5610
28 M), which under physiological conditions, is
reached during the periovulatory phase. Since this estradiol peak
lasts between 1 to 3 days, we wanted to know if exposure of CD4+
T-cells to a high dose of E2 for 1 day would be sufficient to
suppress HIV-infection. Figure 1D shows that 1 day pretreatment
with E2 significantly reduces both released and intracellular p24
levels relative to controls. Overall the same effect was observed
with 3 days or 1 day of pre-treatment with E2 (Figures 1A and 1D
respectively). Equivalent to the results obtained after activation
and E2 treatment for 3 days (Figure 1A), only pre-incubation with
E2 for 1 day had a suppressive effect on HIV infection, and no
inhibition was measured in released or intracellular p24
(Figure 1D, left and right panels) when E2 was added after
infection.
Since these experiments were conducted with cells from both
female and male donors, we analyzed if any differences could be
found between them. As shown in Figure 1E, p24 levels in the
infected controls from female donors were lower than male
donors, with median p24 values of 38,085 versus 71,541
respectively (p = 0.03). To determine whether E2 inhibited HIV
infection of CD4+ T-cells from men and women, cells were
pretreated with E2 for 1 day prior to infection. As seen in
Figure 1E, treatment of CD4+ T-cells from women significantly
reduced HIV-infection (54.9% reduction; p = 0.03), but had no
effect on CD4+ T-cells from men.
We investigated whether the reduction in HlV-susceptibility
induced by E2 could be due to differences in activation. CD4
+ T-
cells treated or not with E2 showed similar expression of CD25 and
HLA-DR before HIV challenge (data not shown).
2. E2 reduces susceptibility of macrophages to HIV-
infection
Recognizing that CD4+ T-cells and macrophages are the most
likely targets for HIV infection, we next focused on the effect of E2
on macrophage infection. Monocyte-derived macrophages were
differentiated in vitro in the presence of E2 for 4 days and infected
with HIV-1BaL. As shown in Figure 2A, similar to our results with
CD4+ T-cells, viral replication was significantly reduced in
macrophages differentiated in the presence of E2 (p,0.0003).
This reduction in susceptibility to HIV-infection was induced by
differentiating the macrophages in the presence of E2 before
infection (pre; 69% reduction) and maintained when E2 was added
back to the culture 2 h after infection (prepost; 73% reduction). In
contrast, E2 had no effect when added immediately after infection
(post) (Figure 2A). Intracellular p24 analysis confirmed a
significant reduction in the percent of p24 positive cells when
macrophages were differentiated in the presence of E2 (Figure 2B
and 2C; p,0.05). Figure 2D demonstrates that intracellular p24
values correspond to de novo infection, since macrophages
infected in the presence of AZT had intracellular p24 values
equal to uninfected controls.
To determine whether HIV infection of macrophages was
influenced by gender, blood derived macrophages from women and
Estradiol Reduces Susceptibility to HIV-Infection
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men were analyzed for HIV infection and responsiveness to E2. In
contrast to CD4+T-cells (Figure 1E), irrespective of donor origin, no
differences in HIV infection were observed. Interestingly, infection
of macrophages derived from female and male donors was
significantly reduced when cells were pretreated with E2.
When Figures 1 and 2 are compared, E2 appears to be more
effective in reducing susceptibility to HIV-infection in macrophages
than CD4+ T-cells. Further, the suppressive effect was maintained
when E2 was present after infection. This maintenance of suppression
represents a difference with respect to the effect observed in CD4+ T-
cells in that the inhibitory effect induced by pre-treatment with E2 is lost
when E2 is present after infection (Figure 1).
3. E2 and ethinyl estradiol (EE) have different effects on
CD4+ T-cell and macrophage susceptibility to HIV-
infection
Recognizing that ethinyl estradiol is the main estrogenic
component in most oral contraceptives and that contraceptives
may be a risk factor for HIV infection [10,35], we investigated if
EE would have the same effect as E2 in preventing HIV-infection
of target cells.
Following the same experimental design described above
(Figure 1), CD4+ T-cells were activated in the presence of EE
and infected with R5 and X4 viral strains. As seen in Figure 3A,
irrespective of the time (pre) and length (prepost/post) of hormone
treatment, and unlike E2 which inhibited HIV infection, EE had
no effect on CD4+ T-cell infection with HIV-1BaL. Similar to the
lack of inhibition with E2, we observed a pattern of reduced HIV-
1IIIb viral replication when EE was added 2 h after infection, but
no statistical significance (Figure 3A, right panel).
In contrast, EE was able to decrease macrophage susceptibility
to HIV-infection. As shown in Figure 3B, when macrophages were
differentiated in the presence of EE, released p24 was significantly
reduced 7 days after infection (p,0.005). When CD4+ T-cells and
macrophages from the same donors were analyzed in parallel to
compare the effects of E2 and EE, intracellular p24 staining
Figure 1. Effect of E2 on HIV-infection of CD4
+ T-cells. A) Released p24 levels in the culture media after 7 days of infection when cells where
pre-treated with E2 for 3 days (pre E2), treated with E2 before and after infection (prepost E2) or only after infection (post E2). Bars represent mean 6
SEM from 7 independent experiments with different donors. *P,0.05. B) Intracellular p24 levels after 7 days of infection, representative of n= 7.
C) Intracellular p24 levels after 7 days of infection in the presence of Zidovudine (AZT). D) Released p24 levels in the culture media (left panel) and
intracellular p24 (right panel) after 7 days of infection when cells where pre-treated with E2 for 1 day (pre E2), treated with E2 before and after
infection (prepost E2) or only after infection (post E2). Bars represent mean6 SEM from 6 independent experiments with different donors. *P,0.05.
E) Released p24 in the culture media after 7 days of infection in CD4+ T-cells from women (black bars; N = 6) or men (grey bars; N = 5). *P,0.05.
doi:10.1371/journal.pone.0062069.g001
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confirmed the lack of effect on CD4+ T-cells but a decrease in the
% of infected macrophages for both E2 and EE pre-treatments
(Figure 3C). Pre-treatment with E2 however, was consistently 10–
20% more effective than EE in suppressing viral replication
(Figure 3D).
4. E2 suppresses HIV-infection in a dose-dependent
manner
To determine if the observed suppression of viral replication
was dose-dependent, serial 10-fold concentrations of E2 were
tested. CD4+ T-cells were incubated with the different doses of E2
for 24 h and then infected with HIV-1BaL. As shown in Figure 4A,
E2 suppressed HIV-infection of CD4
+ T-cells in a dose-dependent
fashion, with 1028 M being the tested concentration that most
effectively suppressed viral replication.
To evaluate the effect of E2 on macrophages, monocytes were
differentiated into macrophages in the presence of serial 10-fold
concentrations of E2 for 4 days and their effect on viral replication
evaluated 7 days post infection. Similar to the effects observed in
CD4+ T-cells, viral replication in macrophages was inhibited by E2
in a dose-dependent manner, with 1028 M being the most
effective concentration (Figure 4B, black bars). As a part of these
studies, we also evaluated the effect of EE on macrophages and
found that EE at 1028 M inhibited viral replication. Consistent
with our previous results, the levels of inhibition were slightly lower
than those obtained with E2.
We then asked if the reduction in HIV-infection induced by E2
was dependent on the dose of viral inoculum used. To investigate
this, we used replication-competent HIV reporter viruses that
encodes BaL env and expresses GFP upon infection. CD4+ T-cells
were treated with E2 for 24 h and then infected with two different
concentrations of virus. As seen in Figure 4C (upper panel),
infection with a MOI of 0.1 corroborated our earlier results,
showing approximately a 50% reduction (5.29 to 2.83%) in
number of GFP+ cells following pre-treatment with E2, but not
when E2 was present both pre- and post-infection (Figure 4C, top
row). In contrast, we found that at higher viral inocula (MOI 1)
(Figure 4C, lower panel), the inhibitory effect of E2 was abrogated.
These findings suggest that E2 induces a saturable mechanism of
HIV-restriction.
5. E2 restriction of viral replication is not due to CCR5
down-regulation
To investigate the possible mechanisms involved in E2
suppression of viral replication, we first examined the expression
of CCR5, the main coreceptor for R5 viral strains. CD4+ T-cells
were activated in the presence of E2 and CCR5 expression was
assayed by RNA and flow cytometry immediately prior to HIV-
Figure 2. Effect of E2 on macrophage HIV-infection. A) Released p24 levels in the culture media after 7 days of infection when cells where pre-
treated with E2 (pre E2), treated with E2 before and after infection (prepost E2) or only after infection (post E2). Bars represent mean 6 SEM from 5
independent experiments with different donors. **P,0.01;***P,0.001. B) Representative contour plot of intracellular p24 levels after 7 days of
infection and C) Fold change respect infected control of intracellular p24 from 4 different donors. Mean 6 SEM is represented. *p,0.05.
D) Intracellular p24 levels after 7 days of infection in the presence of Zidovudine (AZT). E) Released p24 in the culture media after 7 days of infection
in CD4+ T-cells from women (black bars; N = 3) or men (grey bars; N = 3). *P,0.05.
doi:10.1371/journal.pone.0062069.g002
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infection. No differences were observed in CD4+ T-cell CCR5
gene expression after E2 treatment, relative to controls (Figure 5A).
When cells were analyzed for % positive cells and MFI by flow
cytometry, surface expression of CCR5 in response to E2 was
either decreased or increased depending on the donor (Figure 5B)
and showed no correlation with the levels of viral suppression.
Surface expression of CD4 was also measured, but no differences
were found between controls and E2-treated cells (not shown).
To measure viral entry at 2 h post infection [36], CD4+ T-cells
pre-treated with E2 for 24 h were incubated with HIV-1BaL for 2 h
at 37uC, after which free virus was removed by repeated washes.
Cells were then trypsinized, washed and lysed prior to measuring
p24 in the cell lysates by ELISA. As a control, cells were exposed
to the virus for 2 h at 4uC to account for residual extracellular
binding; this background was subtracted from the p24 values
measured at 37uC. Half of the cells were kept in culture and HIV-
infection was followed for 7 days to confirm the inhibitory activity
of E2. As shown in Figure 5C, after 2 h of exposure to the virus,
intracellular levels of p24 were not affected by E2 pre-treatment,
but determination of infection levels 7 days after viral exposure
confirmed suppression of HIV-infection by E2 (Figure 5C).
Macrophages differentiated in the presence of E2 or EE were
also analyzed for the expression of CCR5 at the time of infection.
As seen in Figure 5A, neither E2 nor EE had any effect on CCR5
gene expression relative to controls. Surface expression of CCR5
in macrophages also showed a donor variable scattered pattern
after treatment with E2 that did not correlate with viral
suppression (Figure 5B). Likewise, no differences were found
regarding CD4 or DC-SIGN surface expression (not shown). Viral
entry was then assessed in the same manner described above for
CD4+ T-cells. In contrast to CD4+ T-cells, differentiation of
macrophages in the presence of E2 resulted in a significant
reduction of intracellular p24 after viral exposure for 2 h
(Figure 5D). Interestingly, EE had no effect in reducing viral
entry 2 h after viral challenge, but both E2 and EE reduced
infection levels 7 days after (Figure 5D).
To better define the role of E2 in affecting viral entry, we pre-treated
CD4+ T-cells and macrophages with E2 prior to infection with a single
cycle, VSV-G pseudotyped virus, which enters the cells by endocytosis
and bypasses receptor/coreceptor attachment and fusion [37]. As
shown in Figure 5E, no differences in secreted p24 levels were found
between the control cells and cells pre-treated with E2, strongly
Figure 3. Effect of EE on HIV-infection of CD4+ T-cells and macrophages. A) Released p24 levels in the culture media after 7 days of infection
when CD4+ T-cells where pre-treated with EE (pre EE), treated with EE before and after infection (prepost EE) or only after infection (post EE). Bars
represent mean 6 SEM from 4 independent experiments with different donors. B) Released p24 levels in the culture media after 7 days of infection
when macrophages where pre-treated with EE (pre EE), treated with EE before and after infection (prepost EE) or only after infection (post EE). Bars
represent mean 6 SEM from 4 independent experiments with different donors. **P,0.01. C) Comparison between CD4+ T-cells and macrophages
from the same donors pre-treated with E2 and EE. Dot plots represent percent of p24+ cells. D) Percent of suppression of HIV-infection respect to
infected control in macrophages from the same donors pre-treated with E2 (black dots) or EE (grey dots) in parallel. Each dot represents one
individual.
doi:10.1371/journal.pone.0062069.g003
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suggesting that E2 inhibits infection at the steps of viral attachment or
fusion and not during reverse transcription.
6. Effect of E2 on CCR5 ligand secretion
Since our results suggest that E2 is affecting viral entry, without
down-regulating CD4 and CCR5 expression, we explored the
possibility that E2 treatment alters ligand secretion of RANTES and
MIP-1b, known to block HIV-infection through CCR5 binding.
CD4+ T-cells and macrophages were treated with E2 prior to
infection with HIVBaL after which secretion of RANTES and MIP-
1b was analyzed. As shown in Figure 6A, E2 treatment had no effect
on RANTES secretion by CD4+ T-cells or macrophages. In
contrast, secretion of MIP-1b was significantly increased in
macrophages (Figure 6B), but unaffected by E2 treatment of
CD4+T-cells (Figure 6C, normalized values). These findings suggest
that E2 may reduce viral entry in macrophages by increasing MIP-
1b secretion, which in turn interferes with HIV binding to CCR5 in
macrophages. Whether other ligands are involved in CD4+ T-cell
suppression on HIV infection remains to be determined.
7. Inhibition of HIV-infection by E2 is mediated through
the estrogen receptor (ER)
To further examine the mechanisms involved in the reduction
of HIV-infection by E2, we investigated the role of the estrogen
receptor. First we analyzed expression levels of ERa and ERb in
CD4+ T-cells and macrophages (Figure 7A). Both CD4+ T-cells
and macrophages expressed ERa, with macrophages expression
values approximately 10-fold higher than CD4+ T-cells (median
expression of 0.001 vs 0.00013 respectively; p= 0.005). In contrast,
ERb expression was low compared to ERa in CD4+ T-cells, and
undetectable in macrophages (Figure 7A). To establish that the
effects of E2 are mediated through ER, CD4
+ T-cells and
macrophages were treated with E2 in the presence or not of
Raloxifene, a known preferential ERa antagonist [38]. As seen in
Figure 7B, when cells were pretreated with Raloxifene for 30 min
prior to the addition of E2, Raloxifene reversed the inhibitory
effects of E2 on p24 secretion by CD4
+ T-cells and macrophages.
Importantly, Raloxifene alone had no effect on HIV-infection.
Discussion
In the present study we demonstrate a reduction in HIV-
susceptibility of CD4+ T-cells and macrophages induced by E2. To
the best of our knowledge the data presented here are the first to
show that E2 is involved by a direct mechanism in reducing the
susceptibility to HIV-infection of CD4+ T-cells and macrophages,
the main target cells of HIV. We found that restriction of HIV-
replication in target cells is not due to CCR5 down-regulation and
appears to be mediated through a saturable mechanism of
restriction.
Gender differences regarding HIV-infection are now well
established. At the time of seroconversion women present lower
viral titers than men and, compared to men at similar stages of the
disease, women maintain lower viral loads [4,5]. Despite this
evidence and the known interactions between the immune system
and sex hormones, little is known about the direct effect of E2 in
modulating susceptibility of HIV-target cells to infection. A
paucity of reports previously investigated the direct effects of E2
on HIV infection, but most focused on cells that are not the main
HIV-target cells [23,39,40] or used cell line models that were
already infected [21]. Only one previous report approached the
study of PBMC [24], leaving open the question if the contribution
of E2 was on CD4
+ T-cells, macrophages or other cell subsets such
us CD8+T cells or NK cells.
In our study we observed suppression of HIV-infection in CD4+
T-cells when they were pre-treated with E2 prior but not after
infection. This would be in agreement with a previous study in
which, when E2 was present throughout the experiment, no
hormonal effect was observed with HIV-producing ACH-2
lymphocytes [21].
Our results also demonstrate that pre-treatment with E2 was
able to reduce susceptibility of macrophages to HIV infection with
a more pronounced effect than the one observed for CD4+ T-cells.
Macrophages play a major role in HIV pathogenesis by
contributing to HIV dissemination and establishment of viral
reservoirs. As migratory cells, macrophages can reach enclosed
environments such as the central nervous system that T cells
cannot reach [41]. Our in vitro studies support the hypothesis that
exposure of monocytes to high levels of E2 reached in peripheral
blood during ovulation would render them less susceptible to HIV
infection when they migrate to the tissues and differentiate into
macrophages.
An unexpected finding in our study was that whereas pre-
treatment with E2 protected CD4
+ T-cells from HIV infection,
prolonged exposure post infection, had no effect. Others have
shown that the long terminal repeat of HIV contains a steroid
hormone-responsive element [42] through which E2 enhances
viral replication [22]. This could explain why addition of E2 before
Figure 4. Dose response effect of E2 on HIV-infection. A)
Released p24 levels in the culture media after 7 days of infection when
CD4+ T-cells where pre-treated with indicated doses of E2. Bars
represent mean 6 SEM from triplicates. Representative of 3 indepen-
dent experiments with different donors. *P,0.05 **P,0.01. B) Released
p24 levels in the culture media after 7 days of infection when
macrophages where pre-treated with indicated doses of E2 (black bars)
or EE (grey bars). Bars represent mean 6 SEM from triplicates.
Representative of 3 independent experiments with different donors.
*P,0.05 **P,0.01. C) Percent of GFP positive cells after infection with
HIV-GFP at MOI 1 or MOI 0.1 in CD4+ T-cells pre-treated with E2 (pre E2)
or treated before and after infection (prepost E2).
doi:10.1371/journal.pone.0062069.g004
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and after infection did not have the same effect as pre-treatment
alone in CD4+ T-cells. Alternatively, others have shown cell
surface expression of ERa in T cells, corresponding to the ERa46
isoform, which in response to E2 induces rapid phosphorylation of
ERK and proliferation of T cells [43]. The plasma membrane-
associated form of ER has the ability to rapidly signal in response
to E2 and can ultimately regulate transcriptional activation [44].
These findings suggest that E2 added again after infection,
signaling through membrane-associated ER, could mask the
inhibitory effect of E2 pre-treatment on HIV infection. In
macrophages, however, pre-treatment as well as pre- and post-
treatment inhibited HIV infection while post-infection treatment
with E2 had no effect. Just why these cells differ in their
responsiveness to E2 remains uncertain. What is likely is that an
explanation resides in the unique characteristics of macrophages
given that both CD4+ T-cells and macrophages received the same
virus. Our results indicate that CD4+ T-cells and macrophages
display different ER expression profiles. Macrophages expressed
significantly higher levels of ERa but lacked ERb expression, while
CD4+ T-cells expressed both forms of ER. Taking into consider-
ation that inhibition of HIV-infection in our system is most likely
mediated through ERa, as also indicated by others [45], it is
possible that the differences in ER expression between cell types
may account for the observed differences. Additionally, previous
Figure 5. Effect of E2 on CCR5 expression and viral entry. A) CCR5 expression by RT-PCR. Bars represent mean 6 SEM from 4 different donors.
B) Surface expression of CCR5 after treatment with E2 or EE compared to control. C) p24 detection in cell lysates from CD4
+ T-cells 2 h after infection
(N= 4) and intracellular p24 expression 7 days after infection. D) p24 detection in cell lysates from macrophages 2 h after infection (N= 3) and
intracellular p24 levels 7 days after infection. E) Released p24 in the culture media 3 days after infection with VSV-G pseudotyped HIV. Bars represent
mean 6 SEM from 4 independent experiments with CD4+ T-cells and 3 with macrophages from different donors.
doi:10.1371/journal.pone.0062069.g005
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studies have shown that macrophages [46] and T cells [43] express
different isoforms of ERa, ERa66 and ERa46, and that their
relative expression is modified by E2 [46,47]. Since the ERa46
isoform functions as a repressor of ERa66, differences in the
expression of these isoforms will influence gene regulation [46].
The relative contribution of the different ERa isoforms to the
reduction in HIV-infection induced by E2 remains to be
elucidated. While E2 treatment had no effect on the internalization
of virions two hours after viral challenge in CD4+ T-cells,
macrophages differentiated in the presence of E2 had reduced viral
entry at two hours. These findings could account for the E2
sustained inhibition of HIV infection in macrophages compared to
CD4+ T-cells. As a part of these studies we investigated the early
steps in HIV-infection by using a VSV-G pseudotyped virus,
which does not require coreceptor-mediated attachment and
fusion to enter the cells [37]. Since the viral cycle of VSV-G
pseudotyped virus is the same as replicant competent HIV once
the virus is inside the cell, the lack of differences in infection levels
that we observed between control and E2-treated cells infected
with VSV-G pseudotyped HIV strongly suggests that E2 reduces
HIV-infection by affecting some step before reverse transcription.
Since E2 had no effect on CD4 or CCR5 expression, these findings
suggest that E2 may inhibit HIV infection by stimulating CCR5-
ligand secretion, which on binding to the receptor CCR5,
interferes with HIV binding to this receptor. We found a
significant increase in MIP-1b secretion by E2-treated macro-
phages, but not in CD4+ T-cells, which could account for the
differences observed between cell types. Since MIP-1b, is one of
many ligands that bind CCR5, further studies are needed to more
fully understand the complex mechanisms through which E2
functions to alter susceptibility of HIV-target cells to infection.
An interesting finding in our study was the differences in HIV-
infection and responsiveness to E2 found in immune cells from the
blood of women and men. In the absence of E2, CD4
+ T-cells
from women had lower levels of infection than that found in men.
Additionally, CD4+ T-cells from women were more responsive to
E2 than cells from men. Differential immune responsiveness to E2
treatment by CD4+ T-cells from women and men have been
recently described by Moulton et al [48]. In their study, E2
increased CREMa mRNA expression and down-regulated IL-2
secretion in T cells from women more frequently than from men.
In contrast to CD4+ T-cells, we found no significant differences
between monocyte-derived macrophages from women and men.
Further studies are needed to more fully define the differences in
susceptibility of HIV-target cells from men and women.
Previous studies by us led to the hypothesis of a ‘‘window of
vulnerability’’ in the menstrual cycle during which women are
more susceptible to HIV infection [49]. This hypothesis was based
on studies of the effects of E2 and progesterone on immune
responses in the female reproductive tract both in vitro and during
the menstrual cycle. The present study extends this hypothesis by
demonstrating that E2 directly affects susceptibility of the target
cells to HIV infection in a way that confers protection at a time
when many aspects of the adaptive and innate immune systems are
dampened, to optimize conditions for successful fertilization,
implantation and pregnancy. Our dose response studies indicate
that inhibition in CD4+ T-cells and macrophages is maximal at
561028 M, the concentration known to saturate estrogen
receptors in target cells [50]. This concentration is comparable
to E2 levels at ovulation, and during part of the secretory phase of
the menstrual cycle. Under these conditions, we hypothesize that
while uterine CTL activity as well as innate protection in the
cervix and vagina is suppressed [49,51,52], HIV-target cells would
have reduced susceptibility to infection. Further studies are needed
to determine whether HIV-target cell susceptibility to HIV
infection varies with the menstrual cycle in the female reproduc-
tive tract (FRT). Our results are relevant to understand HIV
pathogenesis, not only as a surrogate in vitro model for the cells
present in the mucosa at the time of exposure, but also given the
fact that CD4+ T-cell and monocyte migration from peripheral
blood into the FRT is hormone and inflammation responsive.
Importantly, our results suggest a protective role for E2 throughout
the FRT at the time when fecundation is likely to occur and HIV,
present in semen, is most likely to be present.
Figure 6. Effect of E2 on CCR5 ligand secretion. A) Levels of RANTES detected in the culture media from CD4
+ T-cells (N = 6) and macrophages
(N= 6) 3 days after infection with HIV-BaL. B) Levels of MIP-1b detected in culture media from CD4+ T-cells (N = 8) and macrophages (N= 6) 3 days
after infection with HIV-BaL. Each dot represents a different donor. C) Box plot of normalized levels of MIP-1b in E2-treated CD4
+ T-cells (white box)
and macrophages (grey box) as compared to the control. Whiskers represent maximum and minimum values. *P,0.05.
doi:10.1371/journal.pone.0062069.g006
Figure 7. Role of estrogen receptor in E2-mediated suppression
of HIV-infection. A) Expression of ERa (black bars) and ERb (grey bars)
detected by real time RT-PCR in CD4+ T-cells (N = 3) and macrophages
(N= 4). Bars represent mean 6 SEM from 3 and 4 different donors for
CD4+ T-cells and macrophages respectively. ND: non-detected. B)
Released p24 detected by ELISA in the culture media of CD4+ T-cells
and macrophages after 7 days of infection. Bars represent mean 6 SEM
from 4 replicates. Representative of 3 independent experiments. Rx:
Raloxifene. *P,0.05.
doi:10.1371/journal.pone.0062069.g007
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Our study indicates that ethinyl estradiol (EE), a known
synthetic estrogen used in many chemical contraceptive formula-
tions (oral, ring, etc) exerts effects on HIV-target cells that are
different from those seen with E2, the naturally occurring estrogen.
While many studies have investigated the interactions between EE
and antiretroviral drugs in HIV-infected women, to the best of our
knowledge, ours is the first study to evaluate the direct effect of EE
in influencing susceptibility of target cells to HIV-infection. In the
present study, while E2 had a clear effect in reducing susceptibility
of CD4+ T-cells to HIV-infection, no significant effect was
observed with EE at the same concentration. Additionally, even
though EE reduced susceptibility of macrophages to HIV-
infection, it was consistently less effective than E2. Lastly, our
studies indicate that EE, unlike E2, played no role in reducing
entry of the virus in macrophages within 2 h. These results
demonstrate that EE is less effective than E2 in reducing
susceptibility of HIV-target cells to infection. EE has a greater
affinity for ER than E2 [50], but the mechanism(s) responsible for
the differential effects between E2 and EE remains to be
determined. As oral contraceptives are a part of multifaceted
preventive strategies, these findings highlight the importance of a
careful evaluation of the impact of hormonal contraception in
HIV-acquisition.
In conclusion, our data indicate that E2 acts directly on CD4
+
T-cells and macrophages to inhibit HIV-infection. These results
should contribute to our understanding of HIV-acquisition and
highlight the importance of considering the influence of menstrual
cycle and hormonal contraceptives when planning new preventive
strategies in women.
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